NDA for the cephalosporin antibiotic cefditoren pivoxil submitted Dec. 28 for acute exacerbations of chronic bronchitis, sinusitis, pharyngitis and skin structure infections in adults and adolescents. TAP is also conducting pediatric studies of Spectracef and plans to file for pediatric indications in the future
You may also be interested in...
Abbott is predicting an early 2001 launch for TAP's cephalosporin antibiotic Spectracef, currently under review at FDA.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011